Investigate can also be ongoing to determine endpoints other than abstinence for measuring treatment efficacy, for instance clinically meaningful reductions in drug use related to improvements in health outcomes (ninety five). This kind of adjustments could reduce the regulatory bar for obtaining FDA approval for new therapeutics. One example is, s